Pravinkumar Patel, MD
Internal Medicine · Fayetteville, NCNPI 1669449179
Payments from drug & device makers
Across 186 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$416
- Amgen$361
- Exact Sciences$272
- AstraZeneca$257
- Novo Nordisk$227
- Lilly USA, LLC$196
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,23597%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 25 | $416 |
| Amgen(2 entities) | 23 | $361 |
| Exact Sciences | 14 | $272 |
| AstraZeneca(2 entities) | 13 | $257 |
| Novo Nordisk | 13 | $227 |
| Lilly USA, LLC | 11 | $196 |
| Astellas Pharma US Inc | 6 | $171 |
| Pfizer | 9 | $155 |
| Johnson & Johnson | 10 | $147 |
| Merck | 7 | $109 |
| Eisai Inc. | 6 | $108 |
| AbbVie | 5 | $96 |
| Irhythm Technologies, Inc. | 2 | $76 |
| Novartis | 4 | $67 |
| Ultragenyx Pharmaceutical Inc. | 3 | $66 |
| Xeris Pharmaceuticals, Inc. | 3 | $53 |
| Philips North America LLC | 3 | $51 |
| Abbott | 3 | $51 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $41 |
| Organogenesis Inc. | 1 | $40 |
| Paratek Pharmaceuticals, Inc. | 2 | $39 |
| Hikma Pharmaceuticals USA | 3 | $38 |
| Nestle Healthcare Nutrition Inc. | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Optinose US, Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Shield Therapeutics Inc | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 2 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Vistapharm, Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Corium, LLC | 1 | $12 |
How this compares
$3,335 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 116 | $101,431 |
| RybelsusSemaglutide | 39 | $62,787 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $39,721 |
| JanuviaSitagliptin Phosphate | 31 | $33,734 |
| JardianceEmpagliflozin | 23 | $31,929 |
| OzempicSemaglutide | 16 | $20,645 |
| LinzessLinaclotide | 13 | $16,535 |
| MyrbetriqMirabegron | 20 | $16,380 |
| TrulicityDulaglutide | 13 | $12,506 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 66 | $11,464 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 509 | $9,044 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $8,869 |
| Spiriva HandihalerTiotropium Bromide | 14 | $7,229 |
| Gabapentin | 324 | $6,637 |
| Atorvastatin Calcium | 406 | $5,077 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $155 | $103,961129 claims |
| Novo NordiskRybelsus, Ozempic | $227 | $83,43355 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $416 | $48,59065 claims |
| MerckJanuvia | $109 | $33,73431 claims |
| Boehringer IngelheimJardiance | $17 | $31,92923 claims |
| AbbVieLinzess | $96 | $16,53513 claims |
| Astellas Pharma US IncMyrbetriq | $171 | $16,38020 claims |
| Lilly USA, LLCTrulicity | $196 | $12,50613 claims |
| Hikma Pharmaceuticals USAEpinephrine | $38 | $2,23111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Fayetteville
- Nitin DesaiFayetteville$6.4M
- Daniel UbaFayetteville$1.2M
- Eugene WrightFayetteville$839K
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.